Abstract
Benzimidazole derivatives 1-24 have been synthesized and their in vitro β-glucuronidase inhibitory activitiy was evaluated. Compounds 15 (IC50 = 6.33 ± 0.40 µM), 7 (IC50 = 22.0 ± 0.33 µM), 2 (IC50 = 23.1 ± 1.78 µM), 17 (IC50 = 23.9 ± 1.46 µM), and 3 (IC50 = 33.8 ± 1.61 µM) showed more potent β-glucuronidase inhibitory activity than the standard (D-saccharic acid 1,4 lactone, IC50 = 48.4 ± 1.25 µM). This study has identified a new series of potential β-glucuronidase inhibitors. A structure-activity relationship has also been studied.
Keywords: Benzimidazole, β-glucuronidase inhibition, glucuronosyl-O-bonds, antihelmintic, anticoagulant, leukaemia, antihistaminic, antihypertensive, dimethylformamide, lepromatous
Medicinal Chemistry
Title:Synthesis and β-Glucuronidase Inhibitory Potential of Benzimidazole Derivatives
Volume: 8 Issue: 3
Author(s): Khalid Mohammed Khan, Momin Khan, Nida Ambreen, Fazal Rahim, Shagufta Naureen, Shahnaz Perveen, M. Iqbal Choudhary and Wolfgang Voelter
Affiliation:
Keywords: Benzimidazole, β-glucuronidase inhibition, glucuronosyl-O-bonds, antihelmintic, anticoagulant, leukaemia, antihistaminic, antihypertensive, dimethylformamide, lepromatous
Abstract: Benzimidazole derivatives 1-24 have been synthesized and their in vitro β-glucuronidase inhibitory activitiy was evaluated. Compounds 15 (IC50 = 6.33 ± 0.40 µM), 7 (IC50 = 22.0 ± 0.33 µM), 2 (IC50 = 23.1 ± 1.78 µM), 17 (IC50 = 23.9 ± 1.46 µM), and 3 (IC50 = 33.8 ± 1.61 µM) showed more potent β-glucuronidase inhibitory activity than the standard (D-saccharic acid 1,4 lactone, IC50 = 48.4 ± 1.25 µM). This study has identified a new series of potential β-glucuronidase inhibitors. A structure-activity relationship has also been studied.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Khan Momin, Ambreen Nida, Rahim Fazal, Naureen Shagufta, Perveen Shahnaz, Iqbal Choudhary M. and Voelter Wolfgang, Synthesis and β-Glucuronidase Inhibitory Potential of Benzimidazole Derivatives, Medicinal Chemistry 2012; 8 (3) . https://dx.doi.org/10.2174/1573406411208030421
DOI https://dx.doi.org/10.2174/1573406411208030421 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) The Current Chemical Utility of Marine and Terrestrial Filamentous Fungi in Side-Chain Chemistry
Current Organic Chemistry GSK-3 Inhibitors: Discoveries and Developments
Current Medicinal Chemistry Medical Treatment of Gastrointestinal Stromal Tumors: State of the Art and Future Perspectives
Reviews on Recent Clinical Trials The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Sphingolipids as Emerging Drug Targets: Therapeutic Applications of Ceramide Analogs
Drug Design Reviews - Online (Discontinued) Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Higher Placental Anti-Inflammatory IL-10 Cytokine Expression in HIV-1 Infected Women Receiving Longer Zidovudine Prophylaxis Associated with Nevirapine
Current HIV Research The Ovary Feels Fine when Paracrine and Autocrine Networks Cooperate with Gonadotropins in the Regulation of Folliculogenesis
Current Pharmaceutical Design vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain
Current Drug Discovery Technologies Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Organic Synthesis of C-Prenylated Phenolic Compounds
Current Organic Chemistry The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Recent Advance in the Research of Flavonoids as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Editorial (Hot Topics: Naturally Occurring Molecules and Anticancer Combination Therapies in the Era of Personalized Medicine and Economic Crisis)
Current Pharmaceutical Design Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Transfer of DNA Encoding Adenoviral E1A
Recent Patents on Anti-Cancer Drug Discovery